Kit for visually detecting epidemic hemorrhagic disease virus as well as use method and application of kit
Through the RT-ERA primer and crRNA combined with CRISPR-Cas12a detection system, high sensitivity, specificity and universal detection of epidemic hemorrhagic viruses is achieved, solving the high detection environment requirements, long cycles and expensive equipment in the prior art The problem is applicable to laboratory and on-site testing.
Patent Information
- Application Number
- CN202411463148.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-21
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-10-21
AI Technical Summary
The prior art lacks efficient, highly sensitive and specific methods for rapid detection of epidemic hemorrhagic virus (EHDV) on the spot, and the existing detection methods require professional equipment or are complicated to operate, and are not suitable for on-site application.
Provide a kit containing RT-ERA primers and crRNA, combined with the CRISPR-Cas12a detection system, visual detection through isothermal amplification and CRISPR-Cas12a reaction, and use real-time fluorescence quantitative PCR instrument, blue light gel cutter or lateral flow detection. The test strips were tested for results.
It realizes high sensitivity, specificity and universality detection of EHDV, and can obtain visual results without relying on precision instruments. It is suitable for laboratory and on-site detection, and overcomes the high requirements of detection environment and periodicity in the prior art. Problems of long, expensive equipment and high false negative rate.
Smart Images

Figure CN119061204A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biological detection, and in particular relates to a kit for detecting epidemic hemorrhagic disease virus and a using method and application thereof. Background Art
[0002] Epizootic haemorrhagic disease (EHD) is an infectious disease caused by the Epizootic haemorrhagic disease virus (EHDV), which is transmitted by Culicoides insect vectors and can infect a variety of wild and domestic ruminants. It is prevalent worldwide. Many ruminants such as deer, cattle, sheep, and alpacas are susceptible to EHDV, among which deer and cattle are the most harmful. The incidence rate of white-tailed deer infected with EHDV is as high as 80%, and the mortality rate is 20-80%. Cattle and sheep infected with EHDV may develop severe hemorrhagic diseases, with clinical manifestations such as fever, loss of appetite, facial edema, conjunctival and oral mucosal congestion, etc. Infection with certain serotypes of the virus can cause abortion and stillbirth in pregnant animals, causing huge economic losses.
[0003] The diameter of EHDV virus particles is about 80nm, with an icosahedral symmetric structure and no envelope. The genome consists of 10 segmented double-stranded RNA (dsRNA), which can encode 7 structural proteins (VP1-VP7) and 4 non-structural proteins (NS1, NS2 and NS3 / NS3A). Among them, VP1, VP4 and VP6 form the internal replicase complex, VP3 and VP7 form the inner capsid of the virus particles, and VP2 and VP5 form the outer capsid of the virus particles. VP7 induces group-specific antibodies; while VP2 induces the host to produce virus-specific neutralizing antibodies, which determines the serotype of EHDV. At present, at least 10 serotypes of EHDV have been identified, namely EHDV-1, 2, 4, 5, 6, 7, 8, 9, 10 and 11, and there is no cross-protection between different serotypes.
[0004] At present, the detection methods of EHDV include virus isolation and identification, serological testing and nucleic acid testing. Among them, virus isolation and identification is the "gold standard", but it has high requirements on laboratory personnel, requires professional training, and is time-consuming. Except for laboratory testing, it is rarely used in the field. Serological testing is currently recognized as a universal inspection method in epidemiological surveys, customs import and export quarantine, animal husbandry, etc., but the operation is complicated and time-consuming, and is also not suitable for field application. RT-PCR and fluorescent RT-PCR detection methods have become the preferred methods for laboratory testing due to their high sensitivity, simple operation and short time, but they require expensive professional equipment and are also not suitable for field testing.
[0005] Therefore, those skilled in the art are eager to develop an efficient, highly sensitive, and highly specific on-site rapid detection method for EHDV that can obtain visual results without relying on precision laboratory instruments. Summary of the invention
[0006] The present invention solves the problem that there is a lack of an efficient, highly sensitive and highly specific method for rapid on-site detection of EHDV in the prior art, and provides a kit for visually detecting epidemic hemorrhagic disease virus and a use method and application thereof.
[0007] One of the objects of the present invention is to provide a kit for visual detection of epidemic hemorrhagic disease virus, the kit comprising RT-EAR primers and crRNA; the forward primer nucleotide sequence of the RT-ERA primer is shown in SEQ ID NO.8, and the reverse primer nucleotide sequence is shown in SEQ ID NO.11; the crRNA comprises: crRNA1 with a nucleotide sequence shown in SEQ ID NO.1 and crRNA2 with a nucleotide sequence shown in SEQ ID NO.2.
[0008] In a preferred embodiment of the present invention, the RT-ERA primers and crRNA are based on the conserved sequence fragment of the EHDV genome segment S1 as a template.
[0009] In a preferred embodiment of the present invention, the amplification system of the RT-ERA primers in the kit is: 4 μL of solvent, 0.5 μL of 10 μM forward primer, 0.5 μL of 10 μM reverse primer, 1 μL of RNA template of the sample to be tested, 3.6 μL of DEPC water, and finally 0.4 μL of activator.
[0010] In a preferred embodiment of the present invention, the kit also includes a CRISPR-Cas12a detection system, which includes: Cas12a 75ng, 10μM crRNA 0.4μL, 10μM ssDNA FQ reporter gene or ssDNA biotin-labeled nucleic acid probe 1μL, Recombinant RNase Inhibitor 0.4μL, 10×Cas12aBuffer 1μL, RT-ERA amplification product to be detected 1-2μL, and DEPC water supplement system to 10μL.
[0011] The second object of the present invention is to provide a method for using the above-mentioned kit for non-diagnostic purposes, and the method comprises the following steps: adding the sample RNA to be tested to the RT-ERA system for isothermal amplification, reacting at 40°C for 20 minutes, and obtaining an RT-ERA amplification product; adding the above-mentioned RT-ERA amplification product to a CRISPR-Cas12a detection system containing crRNA for reaction, reacting at 37°C for 20 minutes, obtaining a reactant, and then performing result detection on the above-mentioned reactant.
[0012] In a preferred embodiment of the present invention, the method of detecting the result in the method of use includes: real-time fluorescence quantitative PCR analysis, blue light gel cutting instrument analysis or lateral flow test strip analysis.
[0013] In a preferred embodiment of the present invention, the detection step of the real-time fluorescence quantitative PCR analysis is: performing a CRISPR-Cas12a detection reaction in a real-time fluorescence quantitative PCR instrument, and setting the fluorescence value to be read every 30 seconds, and performing result detection according to the read fluorescence value.
[0014] In a preferred embodiment of the present invention, the detection step of the blue light gel cutting instrument analysis is: placing the reactant obtained after the CRISPR-Cas12a detection reaction is completed under a blue light gel cutting instrument for observation, taking pictures to record the brightness and color changes of the reaction tube, and when the reaction tube has a fluorescent signal under the blue light gel cutting instrument, it indicates that the test result is positive; when the reaction tube does not have a fluorescent signal under the blue light gel cutting instrument, it indicates that the test result is negative.
[0015] In a preferred embodiment of the present invention, the detection step of the lateral flow test strip analysis is: placing the reactant obtained after the CRISPR-Cas12a detection reaction is completed on the lateral flow test strip to interpret the test result. When the test line T line and the control line C line appear on the test strip at the same time, it indicates that the test result is positive; when only the control line C line appears on the test strip, it indicates that the test result is negative.
[0016] The third object of the present invention is to provide the use of the above-mentioned kit in visual detection of epidemic hemorrhagic disease virus.
[0017] Beneficial effects of the invention: The present invention provides a kit for visual detection of epidemic hemorrhagic disease virus and its use method and application, wherein the kit (RT-ERA / CRISPR-Cas12a system) comprises RT-EAR primers and crRNA, and also comprises RT-ERA amplification system and CRISPR-Cas12a detection system. The kit for visual detection of epidemic hemorrhagic disease virus provided by the present invention has good sensitivity, specificity and universality; firstly, the detection limit of the fluorescence signal reading and the fluorescence signal visualization is 1.7×10 1 copies / μL, and the lower limit of detection of the lateral flow test strip visualization is 1.7×10 2 copies / μL; secondly, the above-mentioned RT-ERA / CRISPR-Cas12a system can complete the specific detection of EHDV nucleic acid, and has no cross-reaction with other arboviral infectious pathogens of ruminants BTV, AKAV, CHUV and common viral infectious pathogens of ruminants PPRV, GPV, BRSV, BRV, BPIV3 and IBRV; finally, the above-mentioned RT-ERA / CRISPR-Cas12a system can complete the nucleic acid detection of at least 8 EHDV serotypes.
[0018] The results of fluorescent RT-PCR laboratory tests on clinically collected blood or tissue samples show that the test results of the visual detection kit for epidemic hemorrhagic disease virus (RT ERA / CRISPR-Cas12a system) provided by the present invention are consistent with the results of fluorescent RT-PCR laboratory tests, indicating that the detection method provided by the present invention can achieve efficient and visual laboratory tests, and is suitable for laboratory testing. The test results based on nucleic acid release and RT ERA / CRISPR-Cas12a system show that the test results of the visual detection kit for epidemic hemorrhagic disease virus (RT ERA / CRISPR-Cas12a system) provided by the present invention have a high rate of conformity with the results of fluorescent RT-PCR laboratory tests, indicating that the above-mentioned detection method can obtain accurate visual detection results without relying on precision instruments, and is suitable for on-site detection work.
[0019] Compared with pathogen isolation, serological detection and nucleic acid detection technologies in the prior art, the kit for visual detection of epidemic hemorrhagic disease virus (RT ERA / CRISPR-Cas12a system) provided by the present invention overcomes the defects of high requirements for detection environment and long detection cycle, expensive detection instruments and reagents, unsuitability for on-site detection, and high false negative result rate in the early stage of pathogen infection; compared with LAMP and RPA isothermal amplification technologies in the prior art, the RT ERA / CRISPR-Cas12a system provided by the present invention overcomes the defects that the specificity and sensitivity of LAMP and RPA isothermal amplification technologies are relatively low, the LAMP isothermal amplification technology requires at least two pairs of primers to complete the detection, and the primers are prone to form dimers to reduce the detection efficiency; compared with the method of using RT-ERA isothermal amplification or CRISPR-Cas12a system alone for detection in the prior art, the RT ERA / CRISPR-Cas12a system provided by the present invention improves the specificity of the detection reaction; the RT Compared with the CRISPR-Cas13a system in the prior art, the ERA / CRISPR-Cas12a system reduces the in vitro transcription step in the detection process, which not only reduces the detection cost but also improves the detection efficiency.
[0020] The RT ERA / CRISPR-Cas12a system provided by the present invention provides a new detection method for EHDV nucleic acid detection, which can be used for clinical sample analysis, on-site detection, daily monitoring and the like in farms, and provides an efficient, convenient and visual technical platform for grassroots detection. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 The figure is the result of the crRNA screening fluorescence reading in Example 1; the Fluorescence ordinate is the fluorescence signal intensity, and the Cycles abscissa is the cycle number; NC is the control group;
[0022] Figure 2 : is the screening result diagram of RT-ERA primers in Example 2; A is the screening result diagram of upstream primers, and B is the screening result diagram of downstream primers;
[0023] Figure 3 Figure 2 is a sensitivity test result diagram of the RT-ERA / CRISPR-Cas12a detection method in Example 2; A is a fluorescence reading result diagram, B is a blue light gel cutting instrument test result diagram, and C is a lateral flow test strip test result diagram;
[0024] Figure 4A is a graph showing the specificity of the RT-ERA / CRISPR-Cas12a detection method in Example 2; A is a graph showing the fluorescence reading result, B is a graph showing the blue light gel cutting instrument detection result, and C is a graph showing the lateral flow test strip detection result;
[0025] Figure 5 This is a graph showing the RT-ERA / CRISPR-Cas12a validation results of EHDV in Example 2;
[0026] Figure 6 The results of the clinical sample laboratory visualization test of the RT-ERA / CRISPR-Cas12a detection method in Example 4;
[0027] Figure 7 This is a comparison diagram of the results of RT-ERA / CRISPR-Cas12a detection and laboratory fluorescent RT-PCR detection based on RNA extraction by TRIzol in Example 4;
[0028] Figure 8 This is a comparison diagram of the results of RT-ERA / CRISPR-Cas12a-test strip detection and laboratory fluorescent RT-PCR detection based on TRIzol RNA extraction in Example 4;
[0029] Figure 9 This is a comparison chart of the results of RT-ERA / CRISPR-Cas12a detection based on RNA released from nucleic acids and laboratory fluorescent RT-PCR detection in Example 4. DETAILED DESCRIPTION
[0030] Those skilled in the art can refer to the content of this article and appropriately improve the process parameters. It should be particularly noted that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The method and application of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content and scope of the present invention to implement and apply the technology of the present invention.
[0031] In order to make the purpose, technical scheme and advantages of the present invention more clear, the present invention is further described in detail below in conjunction with specific embodiments and the accompanying drawings of the specification. The test methods used in the following examples are conventional methods unless otherwise specified, and the materials, reagents, methods and instruments used are conventional materials, reagents, methods and instruments in the art unless otherwise specified, and can be obtained by those skilled in the art through commercial channels.
[0032] HSDNA Polymerase was purchased from Baoriwu Biotechnology Co., Ltd.;
[0033] Recombinant RNase Inhibitor was purchased from Baoriwu Biotechnology Co., Ltd.;
[0034] GeneJET gel extraction kit was purchased from Thermo Fisher Scientific;
[0035] T7 High Yield RNA Transcription Kit was purchased from Nanjing Novogene Biotech Co., Ltd.;
[0036] RT-based nucleic acid amplification reagent (ERA method) was purchased from Suzhou Xianda Gene Technology Co., Ltd.;
[0037] Lateral flow test strips (CRISPR) were purchased from Suzhou Xianda Gene Technology Co., Ltd.;
[0038] Nucleic acid release agent was purchased from Suzhou Xianda Gene Technology Co., Ltd.;
[0039] GenCRISPR TM Cas12a (Cpf1) Nuclease was purchased from GenScript Biotech Co., Ltd.;
[0040] crRNA was synthesized by GenScript Biotech Co., Ltd.;
[0041] DNA sequence synthesis was performed by Beijing Ruiboxingke Biotechnology Co., Ltd.;
[0042] In the following examples, a kit for visually detecting epidemic hemorrhagic disease virus provided by the present invention is referred to as RT-ERA / CRISPR-Cas12a system.
[0043] Example 1: Design and screening of crRNA
[0044] (1) Design of crRNA
[0045] In this example, 8 serotypes of EHDV strains were selected from GenBank as reference sequences, including EHDV-1, EHDV-2, EHDV-4, EHDV-5, EHDV-6, EHDV-7, EHDV-8 and EHDV-10 reference sequences (no EHDV-9 and EHDV-11 reference sequences were available in GenBank); through sequence alignment analysis, the conserved sequence fragment of the EHDV genome segment S1 was selected as the target, and crRNA was designed according to the PAM site, namely crRNA1 (nucleotide sequence is shown in SEQ ID NO.1) and crRNA2 (nucleotide sequence is shown in SEQ ID NO.2), and the crRNA sequence is shown in Table 1.
[0046] Table 1
[0047]
[0048] Note: Y represents the degenerate base C+U; S represents the degenerate base G+C.
[0049] (2) Preparation of DNA template
[0050] In this example, the EHDV genomic segment S1 sequence with a T7 promoter was synthesized and cloned into the pUC57 vector; the PCR reaction volume was 50 μL, consisting of 5× PrimeSTAR Buffer (10 μL), 2.5 mM dNTP Mixture (4 μL), forward primer (1 μL, final concentration 0.2 μM), reverse primer (1 μL, final concentration 0.2 μM), PrimeSTAR HSDNA Polymerase (0.5 μL), template (1 μL, 50 ng), and ddH2O (32.5 μL); the PCR product was purified using a GeneJET gel recovery kit and used as a DNA template for downstream reactions.
[0051] (3) Screening of crRNA
[0052] In this example, the cleavage efficiency of the crRNA-mediated CRISPR-Cas12a system is evaluated. The crRNA1 (nucleotide sequence is shown in SEQ ID NO.1) and crRNA2 (nucleotide sequence is shown in SEQ ID NO.2) obtained in step (1) and crRNA1 and crRNA2 are mixed in an equimolar ratio to obtain three test samples. The three test samples are incubated with the EHDV S1 DNA template obtained in step (2) to detect the cleavage efficiency of the CRISPR-Cas12a detection system. The test results are read by a real-time fluorescence quantitative PCR instrument. The reaction temperature is 37°C, and data are recorded every 30 seconds. A fluorescence data graph is prepared to analyze the crRNA efficiency. The CRISPR-Cas12a detection system has a reaction volume of 10 μL, and comprises Cas12a (75 ng), crRNA (0.4 μL, final concentration 400 nM), ssDNA FQ reporter gene (1 μL, final concentration 1 μM), Recombinant RNase Inhibitor (0.4 μL), 10×Cas12a Buffer (1 μL), DNA template (1 μL) and DEPC water (replenish the system to 10 μL).
[0053] The results are as follows Figure 1As shown, the real-time fluorescence quantitative PCR detection results of the crRNA1 and crRNA2 separate experimental groups and the equimolar mixed experimental group all produced fluorescent signals. Compared with the crRNA2 experimental group and the equimolar mixed experimental group, the experimental group using crRNA1 alone produced a higher fluorescence signal value. Therefore, crRNA1 (nucleotide sequence is shown in SEQ ID NO.1) mediated the cutting efficiency of the CRISPR-Cas12a system to be higher, and crRNA1 was selected for subsequent experiments.
[0054] Example 2: Construction and verification of RT ERA / CRISPR-Cas12a detection system
[0055] (1) Design and screening of isothermal amplification primers
[0056] In this example, according to the crRNA1 (nucleotide sequence shown in SEQ ID NO.1) obtained in Example 1, 6 upstream primers and 8 downstream primers were designed for cross-pairing screening. The primer sequences are shown in Table 2. The RT-ERA product to be tested was obtained by RT-ERA amplification reaction. The volume of the RT-ERA amplification reaction was 10 μL, including a dissolving agent (4 μL), a forward primer (0.5 μL, a final concentration of 500 nM), a reverse primer (0.5 μL, a final concentration of 500 nM), an EHDV RNA template (1 uL), and DEPC water (3.6 μL). Finally, an activator (0.4 μL) was added. The dissolving agent is provided in a commercial RT-ERA kit; the RT-ERA amplification reaction conditions are 40° C. for 20 min. The RT-ERA products of the above-mentioned different primer combinations were drawn for the CRISPR-Cas12a detection system, which had a reaction volume of 10 μL and consisted of Cas12a (75 ng), crRNA (0.4 μL, final concentration 400 nM), ssDNA FQ reporter gene (1 μL, final concentration 1 μM), Recombinant RNase Inhibitor (0.4 μL), 10×Cas12a Buffer (1 μL), RT-ERA product (1-2 μL) and DEPC water (replenishing the system to 10 μL); the reaction conditions of the CRISPR-Cas12a detection system were 37 ° C for 20 min; the reaction was performed by QuantStudio TM 5. Real-time fluorescence quantitative PCR instrument detection to obtain the fluorescence values of different primer combinations.
[0057] The results are as follows Figure 2As shown, first, the downstream primer R3 was selected to screen the amplification efficiency of the upstream primers F1-F6, and the results showed that the upstream primer F6 had the highest amplification efficiency; secondly, the upstream primer F6 was anchored to screen the amplification efficiency of the downstream primers R1-R8, and the results showed that the primer pair of upstream primer F6 (nucleotide sequence shown in SEQ ID NO.8) and downstream primer R3 (nucleotide sequence shown in SEQ ID NO.11) had the highest amplification efficiency.
[0058] Table 2
[0059] Prime name Prime sequence F1 5’-GTTAAAATGCAATGGTCGCAATYACCGTGC-3’ SEQ ID NO.3 F2 5’-GCAATGGTCGCAATYACCGTGCAAGGTGC-3’ SEQ ID NO.4 F3 5’-ATGCAATGGTCGCAATYACCGTGCAAGGTGC-3’ SEQ ID NO.5 F4 5’-GTTAAAATGCAATGGTCGCAATYACCGTG-3’ SEQ ID NO.6 F5 5’-GTTAAAATGCAATGGTCGCAATYACCGT-3’ SEQ ID NO.7 F6 5’-GTTAAAATGCAATGGTCGCAATYACCG-3’ SEQ ID NO.8 R1 5’-TTYYCTCTDAYRCGYCTKATATGDTCTG-3’ SEQ ID NO.9 R2 5’-TGYTTYYCTCTDAYRCGYCTKATATGDTCTG-3’ SEQ ID NO.10 R3 5’-TCCCARGTYGARTCAYGYARAACRGG-3’ SEQ ID NO.11 R4 5’-CYTCCCARGTYGARTCAYGYARAACRG-3’ SEQ ID NO.12 R5 5’-TCYTCCCARGTYGARTCAYGYARAACRGG-3’ SEQ ID NO.13 R6 5’-TTCYTCCCARGTYGARTCAYGYARAACRGG-3’ SEQ ID NO.14 R7 5’-CGYCTKATATGDTCTGAAAAYTTATARAAYTC-3’ SEQ ID NO.15 R8 5’-CTKATATGDTCTGAAAAYTTATARAAYTC-3’ SEQ ID NO.16
[0060] Note: Y represents the degenerate base C+T; D represents the degenerate base G+A+T; R represents the degenerate base A+G; K represents the degenerate base G+T.
[0061] (2) Sensitivity verification of RT ERA / CRISPR-Cas12a detection system
[0062] In this example, the T7 in vitro transcription kit was used to transcribe the RNA template of the EHDV genome segment S1. The in vitro transcription volume was 20 μL, consisting of 10×Reaction Buffer (2 μL), 100 mM ATP / GTP / CTP / UTP (2 μL each), DNA template (2 μL, about 0.5 μg), T7 RNA Polymerase Mix (2 μL) and DEPC water (6 μL). The in vitro transcribed RNA product was then purified using the GeneJET RNA purification and concentration microextraction kit to obtain the EHDV S1 RNA template. In this example, the concentration of 1.7×10 4 , 1.7×10 3 , 1.7×10 2 , 1.7×10 1The EHDV S1 RNA template is prepared by using the RT-ERA amplification kit obtained in step (1) to react, and the obtained RT-ERA amplification product is used as a template for the CRISPR-Cas12a detection system; the CRISPR-Cas12a detection system has a reaction volume of 10 μL, and comprises Cas12a (75 ng), crRNA (0.4 μL, final concentration 400 nM), ssDNAFQ reporter gene or ssDNA biotin-labeled nucleic acid probe (1 μL, final concentration 1 μM), Recombinant RNase Inhibitor (0.4 μL), 10×Cas12a Buffer (1 μL), RT-ERA amplification product (1-2 μL) and DEPC water (replenish the system to 10 μL); CRISPR-Cas12a detection result determination: a. Perform CRISPR-Cas12a detection reaction in a real-time fluorescence quantitative PCR instrument, and set the fluorescence value to be read every 30 seconds; b. Observe under a blue light gel cutting instrument. After the CRISPR-Cas12a detection reaction is completed, take a photo under the blue light gel cutting instrument to record the brightness and color changes of the reaction tube. When a fluorescent signal appears in the reaction tube, the test result is positive, and when no fluorescent signal appears in the reaction tube, the test result is negative; c. Use a lateral flow test strip. After the CRISPR-Cas12a detection reaction is completed, the result is judged by a lateral flow test strip. When the test line T line and the control line C line appear on the test strip at the same time, the test result is positive, and when only the control line C line appears on the test strip, the test result is negative.
[0063] The results are as follows Figure 3 As shown in the figure, the RT ERA / CRISPR-Cas12a detection reaction was carried out using the RNA of the EHDV genome segment S1 as a template. The detection limit based on the fluorescence signal was 1.7×10 1 copies / μL, and the detection limit based on the lateral flow test strip was 1.7×10 2 copies / μL, and the RT ERA / CRISPR-Cas12a detection system can determine the test result within 50 minutes, indicating that the epidemic hemorrhagic disease virus detection method provided by the present invention can achieve high-sensitivity, rapid and visual detection.
[0064] (3) Specificity verification of RT ERA / CRISPR-Cas12a detection
[0065] In this example, bluetongue virus (BTV), akapan virus (AKAV), Zhongshan disease virus (CHUV), peste des petits ruminants virus (PPRV), goat pox virus (GPV), bovine respiratory syncytial virus (BRSV), bovine rotavirus (BRV), bovine parainfluenza virus type 3 (BPIV3) and bovine infectious rhinotracheitis virus (IBRV) were selected as the control group. The above viruses were donated by the cattle and sheep infectious disease research innovation team of Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences.
[0066] According to the RT ERA / CRISPR-Cas12a detection system provided in this example, the above 9 control viruses and EHDV were specifically verified. The results are as follows Figure 4 It is described that, except for the EHDV genomic RNA template, the other 9 control virus genomic RNAs all detected baseline fluorescence signals and negative test strip results, indicating that the visualized epidemic hemorrhagic disease virus detection kit (RT-ERA / CRISPR-Cas12a system) provided by the present invention has high specificity for the detection of EHDV, and has no cross-reaction with other insect-borne viral infectious pathogens of ruminants BTV, AKAV, CHUV and common viral infectious pathogens of ruminants PPRV, GPV, BRSV, BRV, BPIV3 and IBRV.
[0067] (4) Feasibility verification of detecting different serotypes of EHDV
[0068] In this example, an RNA extraction kit was used to extract EHDV-5 and EHDV-7 genomic RNA as samples to be tested, and the S1 segments of EHDV-1, EHDV-2, EHDV-4, EHDV-6, EHDV-8, and EHDV-10 were synthesized, and RNA was transcribed by a T7 in vitro transcription kit as a sample to be tested, and RT-ERA amplification was performed by upstream primer F6 (nucleotide sequence is shown in SEQ ID NO.8) and downstream primer R3 (nucleotide sequence is shown in SEQ ID NO.11), and the RT-ERA amplification product was used as a template for CRISPR-Cas12a detection reaction to verify the feasibility of the RT ERA / CRISPR-Cas12a detection system for detecting different serotypes of EHDV.
[0069] The results are as follows Figure 5As shown, in the RT ERA / CRISPR-Cas12a detection reaction, when EHDV-5 and EHDV-7 genomic RNA, and EHDV-1, EHDV-2, EHDV-4, EHDV-6, EHDV-8 and EHDV-10 genomic segment S1 RNA were used as detection samples, higher fluorescence signal values were detected, confirming that the visualized epidemic hemorrhagic disease virus detection method provided by the present invention is feasible for detecting different serotypes of EHDV.
[0070] Example 3: Preparation of a kit for visual detection of epidemic hemorrhagic disease virus
[0071] The kit described in this embodiment includes RT-EAR primers and crRNA; the forward primer nucleotide sequence of the RT-ERA primer is shown in SEQ ID NO.8, and the reverse primer nucleotide sequence is shown in SEQ ID NO.11; the crRNA includes: crRNA1 with a nucleotide sequence shown in SEQ ID NO.1 and crRNA2 with a nucleotide sequence shown in SEQ ID NO.2;
[0072] The RT-ERA amplification system in the kit is: 4 μL of dissolving agent, 0.5 μL of 10 μM forward primer, 0.5 μL of 10 μM reverse primer, 1 μL of RNA template of the sample to be tested, 3.6 μL of DEPC water, and finally 0.4 μL of activator;
[0073] The kit also includes a CRISPR-Cas12a detection system, which consists of the following components: 75 ng of Cas12a, 0.4 μL of 10 μM crRNA, 1 μL of 10 μM ssDNA FQ reporter gene or 1 μL of ssDNA biotin-labeled nucleic acid probe, 0.4 μL of Recombinant RNase Inhibitor, 1 μL of 10×Cas12a Buffer, 1-2 μL of RT-ERA amplification product to be detected, and DEPC water to supplement the system to 10 μL.
[0074] Example 4: Application of a kit for visual detection of epidemic hemorrhagic disease virus
[0075] In this example, 54 blood and tissue samples were collected clinically, and RNA was extracted from the blood and tissue samples to be tested using TRIzol reagent. At the same time, fluorescent RT-PCR and the kit for visual detection of epidemic hemorrhagic disease virus obtained in Example 3 (hereinafter referred to as RT-ERA / CRISPR-Cas12a system) were used to detect epidemic hemorrhagic disease virus, and the test results were compared and analyzed.
[0076] In this example, the RT-ERA / CRISPR-Cas12a system was used to detect 54 samples to be tested, and the visual results were determined by fluorescence signals and lateral flow test strips. The visual detection results of the lateral flow test strips are shown in Figure 2. Figure 6 As shown, 23 were positive and 31 were negative, with a positive rate of 42.59%; secondly, the laboratory fluorescent RT-PCR detection method was used to detect 54 samples to be tested, and the detection results of RT-ERA / CRISPR-Cas12a fluorescence signals were compared and analyzed with the laboratory fluorescent RT-PCR detection results. The results are shown in Figures 7-8 As shown, the detection results based on the fluorescence signal of the RT-ERA / CRISPR-Cas12a system and the visual detection results based on the lateral flow test strip are consistent with the laboratory fluorescence RT-PCR detection results, indicating that the kit for visual detection of epidemic hemorrhagic disease virus provided by the present invention can be used as a rapid visual detection tool for EHDV nucleic acid.
[0077] In order to verify the feasibility of using a kit for visual detection of epidemic hemorrhagic disease virus for field detection in this example, the 54 blood and tissue samples collected above were subjected to nucleic acid release, 50 μL of the tissue grinding liquid supernatant or 50 μL of the blood was added to 450 μL of nucleic acid releaser, mixed, incubated at 95 ° C for 5 min, centrifuged for 2 min, and then the supernatant was taken for detection of the RT-ERA / CRISPR-Cas12a system. The results were read by fluorescence signals to evaluate the field detection capability.
[0078] The results are as follows Figure 9 As shown, a total of 54 samples were rapidly tested using the nucleic acid releaser and the RT ERA / CRISPR-Cas12a system, with a fluorescence visualization positive rate of 40.74% (22 / 54), which was highly consistent with the laboratory fluorescence RT-PCR detection positive rate of 42.59% (23 / 54); this indicates that the kit for visual detection of epidemic hemorrhagic disease virus provided by the present invention can obtain a visualization detection result with a high consistency with the laboratory fluorescence RT-PCR detection result without relying on precision instruments, and is suitable for on-site detection work at the grassroots level.
[0079] The contents not described in detail in the specification of the present invention are well-known technologies for those skilled in the art. Although the present invention has been disclosed as above with preferred embodiments, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the protection scope of the present invention should be based on the definition of the claims.
Claims
1. A kit for visually detecting epidemic hemorrhagic disease virus, It is characterized in that The kit includes RT-EAR primers and crRNA; The forward primer nucleotide sequence of the RT-ERA primer is shown in SEQ ID NO.8, and the reverse primer nucleotide sequence is shown in SEQ ID NO.11; The crRNA comprises: crRNA1 having a nucleotide sequence as shown in SEQ ID NO.1 and crRNA2 having a nucleotide sequence as shown in SEQ ID NO.
2.
2. The kit according to claim 1, It is characterized in that The RT-ERA primer and crRNA are based on the conservative sequence fragment of the EHDV genome segment S1 as a template.
3. The kit according to claim 1, It is characterized in that The amplification system of the RT-ERA primer in the kit is: 4 μL of solvent, 0.5 μL of 10 μM forward primer, 0.5 μL of 10 μM reverse primer, 1 μL of RNA template of the sample to be tested, 3.6 μL of DEPC water, and finally 0.4 μL of activator.
4. The kit according to claim 1, It is characterized in that The kit also includes a CRISPR-Cas12a detection system, which includes: Cas12a 75ng, 10μM crRNA 0.4μL, 10μMssDNA FQ reporter gene or ssDNA biotin-labeled nucleic acid probe 1μL, Recombinant RNase Inhibitor 0.4μL, 10×Cas12a Buffer 1μL, RT-ERA amplification product to be detected 1-2μL, and DEPC water to supplement the system to 10μL.
5. A method for using the kit according to any one of claims 1 to 4 for non-diagnostic purposes, It is characterized in that The method of use comprises the following steps: adding the sample RNA to be tested to the RT-ERA system for isothermal amplification, reacting at 40°C for 20 minutes, and obtaining an RT-ERA amplification product; adding the above RT-ERA amplification product to a CRISPR-Cas12a detection system containing crRNA for reaction, reacting at 37°C for 20 minutes, obtaining a reactant, and then performing result detection on the above reactant.
6. The method of use according to claim 5, It is characterized in that The method for detecting the result in the method of use includes: real-time fluorescence quantitative PCR analysis, blue light gel cutting instrument analysis or lateral flow test strip analysis.
7. The method of use according to claim 6, It is characterized in that The detection steps of the real-time fluorescence quantitative PCR analysis are as follows: performing a CRISPR-Cas12a detection reaction in a real-time fluorescence quantitative PCR instrument, setting the fluorescence value to be read once every 30 seconds, and performing result detection according to the read fluorescence value.
8. The method of use according to claim 6, It is characterized in that The detection steps of the blue light gel cutting instrument analysis are: placing the reactants obtained after the CRISPR-Cas12a detection reaction is completed under a blue light gel cutting instrument for observation, taking pictures to record the brightness and color changes of the reaction tube, and when the reaction tube shows a fluorescent signal under the blue light gel cutting instrument, it indicates that the test result is positive; when the reaction tube does not show a fluorescent signal under the blue light gel cutting instrument, it indicates that the test result is negative.
9. The method of use according to claim 6, It is characterized in that The detection step of the lateral flow test strip analysis is: placing the reactant obtained after the CRISPR-Cas12a detection reaction is completed on the lateral flow test strip to interpret the test result. When the test line T line and the control line C line appear on the test strip at the same time, it indicates that the test result is positive; when only the control line C line appears on the test strip, it indicates that the test result is negative.
10. Use of the kit according to any one of claims 1 to 4 in visual detection of epidemic hemorrhagic disease virus.
Citation Information
Patent Citations
Fluorescent quantitative RT-PCR primer, probe and kit for identifying serotype of epidemic hemorrhagic disease virus
CN111500773A
RPA-LFD primer, probe and kit for jointly detecting epidemic hemorrhagic disease virus and Palimer serum group virus
CN113265488A
CRISPR-Cas12a-based African horse pestivirus visual rapid detection method and kit thereof
CN116064963A
Kit for detecting epidemic hemorrhagic fever virus and application thereof
CN116732246A
CRISPR-Cas12a-based BVDV specific crRNA and related kit and detection method thereof
CN117737069A
Cited By
Quadruple fluorescent quantitative RT-PCR (Reverse Transcription-Polymerase Chain Reaction) detection kit for detecting ruminant arthroviruses as well as use method and application
CN119639966A
